Articles: 26.19 5 October 2015

Dulaglutide is a once-weekly GLP-1 receptor agonist for the treatment of type 2 diabetes. Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Stephen Bain discusses its place in therapy.
Dulaglutide a once-weekly GLP-1 for type 2 diabetes

The dermatophyte skin infections tinea capitis, tinea pedis and onychomycosis are common and challenging to treat. This review focuses on key points and recent guidelines on the diagnosis and management of fungal skin infections.
Fungal skin infections current approaches to management

This is the first in a series of eight articles that will discuss the recommendations pertaining to medication safety, and provide insights into their application and implications for practice.
Learning from medicine related safety incidents

Antidepressant use in Western countries doubled between 2003 and 2013. By 2014, 11 per cent of adults in England were taking them, costing £280 million annually. While antidepressants can be used for pain and insomnia, the large majority are prescribed for depression and anxiety disorders.
Long-term …

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. Edoxaban (Lixiana) is, like rivaroxaban (Xarelto) and apixaban (Eliquis), an oral direct inhibitor of Factor Xa.
New from NICE

Statistics from the Health and Social Care Information Centre give an overview of tends in prescribing over the past 10 years. Here we outline the main shifts in practice.
Trends in primary care prescribing

Registration is for health professionals only and gives free access to our content.

Your Name (required)

Your Email (required)

Job Title (required)

Other Job Title

Interests (required)

Country (required)

Would you also like to receive the print title?Yes (please complete address details below)No

Address Line 1

Address Line 2

Town/City

County

Postcode

By submitting your email address you consent to receive occasional relevant email alerts from Prescriber. Your email will not be shared with any third party. Please note you can opt out by replying to any email with the words ‘unsubscribe’.